Navigation Links
Bioniche Reports Fiscal 2008 Third Quarter
Date:5/9/2008

mber of common

shares

outstanding 62,791,700 44,274,985 62,246,607 41,242,672

Bioniche Life Sciences Inc.

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

For the three and nine months ended March 31

Current Last Year Current Last

Quarter Quarter Year to Date Year to Date

2008 2007 2008 2007

$ $ $ $

-------------------------------------------------------------------------

OPERATING ACTIVITIES

Net loss for the

period (4,642,310) (4,510,434) (12,672,233) (10,164,369)

Add (deduct)

non-cash items:

Amortization 805,863 641,096 1,951,089 2,469,459

Accreted interest

on convertible

term note - 59,831 - 679,244

Change in

unrealized loss

(gain) on

foreign currency

embedded

derivative 191,096 - 52,893 -

Unrealized foreign

exchange loss

(gain) 231,039 (8,914) 177,593 336,730

Stock-based

compensation 94,585 55,242 273,559 166,264

Share compensation 126,719 - 380,156 81,000

Employee share

ownership plan 188,061 146,256 499,383 358,918

Impairment of

investment - - - 175,000

Loss on sale of

investment - - - 17,157

Gain on sale of

right to future

royalty stream - - -
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Bioniche Appoints U.S. President of Food Safety
2. Bioniche Reports the Passing of its Board Chair
3. Bioniche Converts a Portion of its Debt to Equity
4. Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy
5. Bioniche Pharma Chooses TrackWise for its Deviation Control Solution
6. Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
7. Bioniche Reports Fiscal 2008 Second Quarter
8. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
9. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
10. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
11. Bioniche Reports Fiscal 2008 First Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2008)...art to avoid devastating vision injuries, group sa... -- Every year in the United States, about 40,000 ...e American Academy of Ophthalmology (AAO), which r...ts-specific eye protection properly fitted by an e...rbonate materials offer the highest level of impac...
(Date:5/9/2008)...RNewswire-FirstCall/ -- Cynosure, Inc.,(Nasdaq: C...road array of,light-based aesthetic treatment syst...pproval from the Korea Food & Drug Administration ...or the removal of pigmented,lesions., Introduced ...third,Cynosure flagship product approved for marke...
(Date:5/9/2008)...ated for Maintenance Treatment for ADHD, INDIANAP...d Company,(NYSE: LLY ) announced today that the U...s approved Strattera(R) (atomoxetine HCI) for,main...ty Disorder (ADHD) in,children and adolescents. St...itor, is the first FDA-approved non-stimulant to t...
(Date:5/9/2008).../PRNewswire-USNewswire/ -- International,Rescue Co...nmar and four,additional teams are on standby for ... possible outbreak of water-borne diseases in cycl...estroyed in the villages I assessed today and,the ...ng water," says the,IRC,s emergency coordinator, G...
Breaking Medicine News(10 mins):Health News:Protective Eyewear Key to Sports Safety 2Health News:Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval 2Health News:Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval 3Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 2Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 3Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 4Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 5Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 6Health News:International Rescue Committee Mobilizes More Emergency Teams for Myanmar; Warns of Massive Health Disaster Unless Aid Reaches Cyclone Survivors Fast 2
... most common causes for referral to the emergency ...ent, is not an emergency, and intravenous treatmen...w to treat patients with acute BP elevation or exc... excessive hypertension and therefore antianxiety ...
...ave reconstructed defective windpipes using tissue...amniotic fluid for growing the sections of cartila... into lambs, while they were in the womb. This tec... birth defects. Undifferentiated stem cell from am...
...trains might have spawned an outbreak of disease a...uver Island, British Columbia, Howard Hughes Medic...l Center have reported//. The fungus, Cryptococcus...ropics and subtropics. The evidence that sex play...
...ritish High Commission organized a seminar to expl...India along with joint ventures in services and ma...ade and Investment's (UKTI) healthcare mission to ...rs in Chennai on Wednesday. The British delegation...
Other Medicine News:Health News:Anti-anxiety treatment found effective in lowering blood pressure 2Health News:Sex Played A Vital Role For Evolution Of Infectious Diseases 2
(Date:5/9/2008)...PA, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoar...condition that affects almost 50,million people in...of,cartilage in bone joints. The novel investigati...g oral analgesic, provided significant relief,for ...e treated with,placebo, and with fewer gastrointes...
(Date:5/9/2008)...sts Cytopia,s development of early pipeline cancer...Newswire-FirstCall/ -- Cytopia Limited,(ASX: CYT) ...ancer drug,discovery and development collaboration...ent leverages Cytopia,s early stage drug discovery...d therapeutics that is one of the,fastest growing ...
(Date:5/8/2008)...STON, May 8 /- The Cancer Research Al...ion,s top cancer centers, is asking,303 million Am...ating $1 to,cancer research efforts this Mother,s ...he "Infinite Power of One(TM)" has two key goals:,...nto their own hands by,joining together to exercis...
(Date:5/8/2008)...eatment Provides "Blueprint" to Produce Therapeuti...l., May 8 /PRNewswire-USNewswire/ -- Using gene,th...ting proteins through,skin flaps placed on cancero...umor volume, according to a study in the May issue...icial medical journal of the American,Society of P...
Breaking Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 2Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3AMDL Announces Sales of 245 8 Million for Third Quarter 2007 Results 6672 1AMDL Announces Sales of 245 8 Million for Third Quarter 2007 Results 6672 2BREATHE Lung Cancer Conference Nov 30 Offers Medical and Patient Education Advocacy and Survivors Perspective 6670 1BREATHE Lung Cancer Conference Nov 30 Offers Medical and Patient Education Advocacy and Survivors Perspective 6670 2BREATHE Lung Cancer Conference Nov 30 Offers Medical and Patient Education Advocacy and Survivors Perspective 6670 3BREATHE Lung Cancer Conference Nov 30 Offers Medical and Patient Education Advocacy and Survivors Perspective 6670 4BREATHE Lung Cancer Conference Nov 30 Offers Medical and Patient Education Advocacy and Survivors Perspective 6670 5BREATHE Lung Cancer Conference Nov 30 Offers Medical and Patient Education Advocacy and Survivors Perspective 6670 6AMICAS Solutions Closing the Loop in Radiology Communications 6668 1AMICAS Solutions Closing the Loop in Radiology Communications 6668 2AMICAS Solutions Closing the Loop in Radiology Communications 6668 3AMICAS Solutions Closing the Loop in Radiology Communications 6668 4Thoratec Announces Appointment of Steven H Collis to Board of Directors 1857 1Thoratec Announces Appointment of Steven H Collis to Board of Directors 1857 2Thoratec Announces Appointment of Steven H Collis to Board of Directors 1857 3
...INESS WIRE)--Apr 17, 2007 - A 9-month, randomized,... patients,comparing a 40 mg dose of COPAXONE(R) gi... mg dose showed a 38 percent greater,reduction in ...tic,resonance images (MRI) of the brain. In additi...a reduced mean on-trial relapse rate,of 77 percent...
...tions at American Association for Cancer Research,.../PRNewswire-FirstCall/ --,Medarex, Inc. today pres...tumor activity from two separate studies exploring...CD19 and anti-CD70,antibody-drug conjugates. CD19 ...dy-drug conjugate approach to cancer therapy. They...
Other Medicine Technology:Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 2Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 3Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 5Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 2Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 3Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 4
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
Medicine Products: